Nurix Therapeutics shares rose 15.7% to $16.94 after the company announced a collaboration and licensing agreement with Roche for its blood cancer treatment bexobrutideg. The deal strengthens Nurix's pipeline and provides external validation from a large pharma partner. The move is material for the stock and could support sentiment across the biotech name.
Nurix Therapeutics shares rose 15.7% to $16.94 after the company announced a collaboration and licensing agreement with Roche for its blood cancer treatment bexobrutideg. The deal strengthens Nurix's pipeline and provides external validation from a large pharma partner. The move is material for the stock and could support sentiment across the biotech name.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
